Mosquirix (RTS,S)

A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria

Kyle J Wilby BSP ACPR, PharmD; Tim TY Lau PharmD ACPR FCSHP; Samuel E Gilchrist MSc (Pharm), PhD; Mary HH Ensom PharmD FASHP FCCP FCSHP FCAHS


The Annals of Pharmacotherapy. 2012;46(3):384-393. 

In This Article

Data Sources

A literature search was performed using the terms Mosquirix; RTS,S; malaria; vaccine; and Plasmodium in MEDLINE (1948-November 2011), EMBASE (1980-November 2011), International Pharmaceutical Abstracts (1970-November 2011), Google, and Google Scholar. Articles were identified describing the vaccine through all states of development and characterizing its pharmacology, pharmacokinetics, efficacy, and safety. For all studies, malarial disease acquisition was defined as development of fever (axillary temperature ≥37.5 °C) with documented P. falciparum infection. Severe disease was defined based on each individual study. Information regarding study design, population, study period, baseline characteristics, clinical outcomes, results, and assessors of quality was extracted from each of these trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.